GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ambrx Biopharma Inc (NAS:AMAM) » Definitions » Cost of Goods Sold

Ambrx Biopharma (Ambrx Biopharma) Cost of Goods Sold : $0.00 Mil (TTM As of Jun. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Ambrx Biopharma Cost of Goods Sold?

Ambrx Biopharma's cost of goods sold for the three months ended in Jun. 2023 was $0.00 Mil. Its cost of goods sold for the trailing twelve months (TTM) ended in Jun. 2023 was $0.00 Mil.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Ambrx Biopharma's Gross Margin % for the three months ended in Jun. 2023 was 100%.

Cost of Goods Sold is also directly linked to Inventory Turnover.


Ambrx Biopharma Cost of Goods Sold Historical Data

The historical data trend for Ambrx Biopharma's Cost of Goods Sold can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ambrx Biopharma Cost of Goods Sold Chart

Ambrx Biopharma Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Cost of Goods Sold
- - - -

Ambrx Biopharma Quarterly Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Cost of Goods Sold Get a 7-Day Free Trial - - - - -

Ambrx Biopharma Cost of Goods Sold Calculation

Cost of Goods Sold is the aggregate cost of goods produced and sold, and services rendered during the reporting period. It excludes Total Operating Expense, such as Depreciation, Depletion and Amortization and Selling, General, & Admin. Expense.

Cost of Goods Sold for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ambrx Biopharma  (NAS:AMAM) Cost of Goods Sold Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Ambrx Biopharma's Gross Margin % for the three months ended in Jun. 2023 is calculated as:

Gross Margin %=(Revenue - Cost of Goods Sold) / Revenue
=(1.147 - 0) / 1.147
=100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Cost of Goods Sold is also directly linked to another concept called Inventory Turnover:

Ambrx Biopharma's Inventory Turnover for the three months ended in Jun. 2023 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher inventory turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate inventory turnover. An average inventory is a better indication.


Ambrx Biopharma Cost of Goods Sold Related Terms

Thank you for viewing the detailed overview of Ambrx Biopharma's Cost of Goods Sold provided by GuruFocus.com. Please click on the following links to see related term pages.


Ambrx Biopharma (Ambrx Biopharma) Business Description

Traded in Other Exchanges
Address
10975 North Torrey Pines Road, La Jolla, CA, USA, 92037
Ambrx Biopharma Inc is a clinical-stage biologics company focused on discovering and developing a novel class of engineered precision biologics (EPBs) using its proprietary expanded genetic code technology platform that allows incorporating synthetic amino acids (SAAs) into proteins within living cells. Its product pipeline includes ARX788, ARX517, ARX305 among others.
Executives
Cormorant Asset Management, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Margaret Dalesandro director ONCOSEC MEDICAL INCORPORATED, 24 NORTH MAIN STREET, PENNINGTON NJ 08534
Sonja Nelson officer: Chief Financial Officer C/O MOTUS GI HOLDINGS, INC., 1301 EAST BROWARD BOULEVARD, 3RD FLOOR, FT. LAUDERDALE FL 33301
Daniel J. O'connor director, officer: President and CEO C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
Abhishek Trehan 10 percent owner WHITELEY CHAMBERS, DON STREET, ST. HELIER Y9 JE2 4TR
Darwin Global Master Fund, Ltd. 10 percent owner C/O OGIER GLOBAL (CAYMAN) LIMITED, 89 NEXUS WAY, CAMANA BAY, GRAND CAYMAN E9 KY1-9009
Paul V Maier director 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Janet Loesberg director C/O AMBRX BIOPHARMA INC., 10975 NORTH TORREY PINES ROAD, LA JOLLA CA 92037
Kate Hermans director C/O AMBRX BIOPHARMA INC., 10975 TORREY PINES ROAD, LA JOLLA CA 92037
Xiaowei Chang director 10975 NORTH TORREY PINES ROAD, LA JOLLA CA 92037
Stephen C. Glover director 108 DOCKSIDE CIRCLE, WESTON FL 33327
Andrew Aromando officer: Chief Operating Officer C/O AMBRX BIOPHARMA INC., 10975 NORTH TORREY PINES ROAD, LA JOLLA CA 92037
Cormorant Private Healthcare Fund Iii Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Global Healthcare Master Fund, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Bihua Chen 10 percent owner C/O CORMORANT ASSET MANAGEMENT, LP, 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116